Asterand collaborates with Rubicon on cancer diagnostics
Asterand, a UK human tissue research services company, says that it has signed a partnership with USA-based Rubicon Genomics to discover novel biomarkers for cancer diagnosis.
Under the non-exclusive agreement, Asterand will supply tissue and biofluid samples from its biorepository and its worldwide network of clinical collaborators. Rubicon will perform retrospective and prospective studies with the samples using its proprietary MethylPle technology to discover more sensitive and specific methylated DNA markers for cancer diagnosis and prognosis.
DNA methylation is an important mechanism by which cells become cancerous and grow out of control. Several recent studies have shown that specific methylated DNA sequences can be detected in the blood of various cancer patients. Thus, these modified DNAs can be sensitive markers for the presence of cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze